Digest Network Come funziona
Network
/
Società
Gi
Non verificato

Gilead Sciences, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteSanità

98 comunicati stampa

Guarda tutti i comunicati
21/01/2026
Scienza
Comunicazione
Medicina - Varie
Sanità
Farmaceutica
Salute
Oncologia
Industria
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
22/12/2025
Web e Social Network
Fiere
Eventi
Biotecnologia
Farmaceutica
Salute
Gilead Sciences to Present at Upcoming Investor Conference
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
22/12/2025
Multimedialità
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Farmaceutica
Biotecnologia
Industria
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
19/12/2025
Mercato del lavoro
Industria
HIV, AIDS e malattie autoimmuni
Sanità
Politica Interna
Biotecnologia
Farmaceutica
Salute
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
18/12/2025
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
15/12/2025
Industria
HIV, AIDS e malattie autoimmuni
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
09/12/2025
Industria
Oncologia
Associazioni/Professionisti
Salute
Sanità
Farmaceutica
Biotecnologia
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
07/12/2025
Industria
Scienza
Sanità
Igiene alimentare
Medicina - Varie
Biotecnologia
Farmaceutica
Salute
Oncologia
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
06/12/2025
Industria
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
06/12/2025
Eventi
Industria
Oncologia
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0